Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma
Retinoids are an important component of neuroblastoma therapy at the stage of minimal residual disease, yet 40-50% of patients treated with 13-cis-retinoic acid (13-cis-RA) still relapse, indicating the need for more effective retinoid therapy. Vorinostat, or Suberoylanilide hydroxamic acid (SAHA), is a potent inhibitor of histone deacetylase (HDAC) classes I & II and has antitumor activity in vitro and in vivo. Fenretinide (4-HPR) is a synthetic retinoid which acts on cancer cells through both nuclear retinoid receptor and non-receptor mechanisms.
Source: Molecular Oncology - Category: Cancer & Oncology Authors: Belamy B. Cheung, Owen Tan, Jessica Koach, Bing Liu, Michael SY. Shum, Daniel R. Carter, Selina Sutton, Sela T. Po’uha, Louis Chesler, Michelle Haber, Murray D. Norris, Maria Kavallaris, Tao Liu, Geraldine M. O’Neill, Glenn M. Marshall Source Type: research